Last reviewed · How we verify
BCG Vaccine IP - Serum Institute of India
BCG Vaccine IP - Serum Institute of India is a Live attenuated vaccine Biologic drug developed by Green Signal Biopharma Private Limited. It is currently in Phase 3 development for Tuberculosis prevention in infants and high-risk populations, Potential immunotherapeutic use in bladder cancer (investigational). Also known as: BCG Vaccine IP (SIIL).
BCG vaccine stimulates the immune system to recognize and attack tuberculosis-causing bacteria through activation of T-cells and macrophages.
BCG vaccine stimulates the immune system to recognize and attack tuberculosis-causing bacteria through activation of T-cells and macrophages. Used for Tuberculosis prevention in infants and high-risk populations, Potential immunotherapeutic use in bladder cancer (investigational).
At a glance
| Generic name | BCG Vaccine IP - Serum Institute of India |
|---|---|
| Also known as | BCG Vaccine IP (SIIL) |
| Sponsor | Green Signal Biopharma Private Limited |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
BCG (Bacillus Calmette-Guérin) is a live attenuated mycobacterium that primes cellular immunity against Mycobacterium tuberculosis. It works by inducing both CD4+ and CD8+ T-cell responses and activating macrophages to provide protection against tuberculosis infection and disease progression.
Approved indications
- Tuberculosis prevention in infants and high-risk populations
- Potential immunotherapeutic use in bladder cancer (investigational)
Common side effects
- Local reaction at injection site (erythema, induration)
- Regional lymphadenitis
- Fever
- BCG-itis (disseminated infection, rare)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BCG Vaccine IP - Serum Institute of India CI brief — competitive landscape report
- BCG Vaccine IP - Serum Institute of India updates RSS · CI watch RSS
- Green Signal Biopharma Private Limited portfolio CI
Frequently asked questions about BCG Vaccine IP - Serum Institute of India
What is BCG Vaccine IP - Serum Institute of India?
How does BCG Vaccine IP - Serum Institute of India work?
What is BCG Vaccine IP - Serum Institute of India used for?
Who makes BCG Vaccine IP - Serum Institute of India?
Is BCG Vaccine IP - Serum Institute of India also known as anything else?
What drug class is BCG Vaccine IP - Serum Institute of India in?
What development phase is BCG Vaccine IP - Serum Institute of India in?
What are the side effects of BCG Vaccine IP - Serum Institute of India?
Related
- Drug class: All Live attenuated vaccine drugs
- Manufacturer: Green Signal Biopharma Private Limited — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Tuberculosis prevention in infants and high-risk populations
- Indication: Drugs for Potential immunotherapeutic use in bladder cancer (investigational)
- Also known as: BCG Vaccine IP (SIIL)